Share Twitter LinkedIn Facebook Email Dr. Leora Horn of Vanderbilt University reviews the rapidly evolving issue and growing value of repeat biopsies, including plasma sampling as a “liquid biopsy” option, in the setting of acquired resistance to a driver mutation in advanced NSCLC.
What is the new treatment for non-small cell lung cancer? Changes in the Perioperative Setting [54 Slides] Karen Reckamp, MD Non-Small Cell Lung Cancer 4 Mins Read
FDA Approves Amivantamab with Chemo for First-Line NSCLC with EGFR Exon 20 Insertion Mutations [EXCLUSIVE VIDEO] Non-Small Cell Lung Cancer 3 Mins Read
New FDA Approval: Osimertinib (TAGRISSO®) Combined with Chemotherapy for Treating EGFR-Mutated NSCLC Non-Small Cell Lung Cancer 4 Mins Read